The MYC axis in advanced prostate cancer is impacted through concurrent targeting of ERβ and AR using a novel ERβ-selective ligand alongside EnzalutamideJaimie S. Gray, Moray J. Campbell|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 4
Epigenetic disruption of the RARγ complex impairs its function to bookmark AR enhancer interactions required for enzalutamide sensitivity in prostate cancerSajad A. Wani, Moray J. Campbell|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 1